Now the primary focus of Iksuda Therapeutics will be on the development of superior ADCs for treatment of difficult-to-treat cancers
Glythera, the next-generation antibody drug conjugate (ADC) development company, has changed its name to Iksuda Therapeutics and unveiled a new corporate brand.
The new identity signifies the company’s transition from technology licensing to drug development, focusing on cancer therapeutics and the treatment of solid tumours. To coincide with the rebranding, Iksuda Therapeutics has also launched a new website: www.iksuda.com.
Iksuda’s primary focus will be on the development of superior ADCs for treatment of difficult-to-treat cancers, but the company will continue to support its partners’ portfolios with its advanced conjugation platform, PermaLink and novel toxin payloads.
Iksuda anticipates that it will nominate two ADCs for clinical progression in Q4 2018, with first indications expected to be ovarian and lung cancers. To support its preclinical and clinical activities, the company has significantly expanded its team in the past 12 months, including the appointment of Dr Robert Lutz’s as CSO in January 2018.
Dr Dave Simpson, CEO of Iksuda, said: “The name Iksuda is derived from the Sumerian word for ‘all conquering’ and was chosen to reflect our ambition of overcoming the issue of ADC instability to create a new generation of stable, effective ADCs for treating the most severe cancers and improving patient lives.”